Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 2:15 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 51 matching trials from the live ClinicalTrials.gov search.
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety and Pharmacokinetics of a Single Dose of CCH (3.36 mg) in Subjects With EFP

NCT03675685
Conditions
Edematous Fibrosclerotic Panniculopathy
Interventions
CCH (collagenase clostridium histolyticum)
Biological
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years and older · Female only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Peyronie's Disease
Interventions
Xiaflex® 0.58 mg
Drug
Lead sponsor
Manhattan Medical Research Practice, PLLC
Industry
Eligibility
18 Years and older · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
New York, New York
Conditions
Edematous Fibrosclerotic Panniculopathy, Cellulite
Interventions
COLLAGENASE CLOSTRIDIUM HISTOLYTICUM, Placebo Comparator
Biological
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years and older · Female only
Enrollment
375 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
16
States / cities
Beverly Hills, California • Murrieta, California • Oceanside, California + 12 more
Conditions
Lipoma
Interventions
AA4500, placebo
Drug
Lead sponsor
Gerut, Zachary, M.D.
Individual
Eligibility
18 Years to 75 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
2
States / cities
Hewlett, New York • Nashville, Tennessee
Conditions
Dupuytren's Contracture
Interventions
collagenase clostridium histolyticum, Placebo
Biological
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years and older
Enrollment
308 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
15
States / cities
Los Angeles, California • Palo Alto, California • Denver, Colorado + 12 more
Conditions
Dupuytren's Disease
Interventions
XIAFLEX
Biological
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
35 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
New York, New York
Conditions
Dupuytren's Disease
Interventions
Clostridial collagenase injectable
Biological
Lead sponsor
Indiana Hand to Shoulder Center
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
2
States / cities
Indianaplis, Indiana • Stony Brook, New York
Conditions
Dupuytren's Contracture
Interventions
AA4500 collagenase clostridium histolyticum
Biological
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
4
States / cities
Tucson, Arizona • Indianapolis, Indiana • Stony Brook, New York + 1 more
Conditions
Peyronie Disease
Interventions
Collagenase Clostridium Histolyticum, RestoreX, Sildenafil
Drug · Device
Lead sponsor
Charitable Union for the Research and Education of Peyronie's Disease
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Orem, Utah
Conditions
Cellulite, Laxity; Skin, Edematous Fibrosclerotic Panniculopathy
Interventions
Not listed
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years to 55 Years · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
3
States / cities
Coral Gables, Florida • Metairie, Louisiana • New York, New York
Completed Phase 3 Interventional Results available

Study of AA4500 in the Treatment of Peyronie's Disease

NCT01221623
Conditions
Peyronie's Disease
Interventions
AA4500, Placebo
Biological
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years and older · Male only
Enrollment
418 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
29
States / cities
Mobile, Alabama • Anchorage, Alaska • Phoenix, Arizona + 26 more
Conditions
Plantar Fasciitis
Interventions
Collagenase Clostridium Histolyticum (CCH), Placebo
Biological
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
231 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
39
States / cities
Tucson, Arizona • Castro Valley, California • Corona, California + 32 more
Conditions
Edematous Fibrosclerotic Panniculopathy, Cellulite
Interventions
CCH-aaes, Antifibrinolytic Agent
Drug
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years to 60 Years · Female only
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
13
States / cities
Scottsdale, Arizona • Beverly Hills, California • Encinitas, California + 10 more
Conditions
Peyronie Disease, Erectile Dysfunction
Interventions
Collagenase Clostridium Histolyticum, Storz Duolith LiSWT
Drug · Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Male only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Completed Phase 3 Interventional Results available

Collagenase in the Treatment of Dupuytrens Disease

NCT00260429
Conditions
Dupuytren's Disease
Interventions
collagenase clostridium histolyticum
Biological
Lead sponsor
Stony Brook University
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
Stony Brook, New York
Conditions
Adhesion of Flexor Tendon of Hand
Interventions
Collagenase, Collagenase injection
Drug
Lead sponsor
Stony Brook University
Other
Eligibility
18 Years to 75 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Stony Brook, New York
Conditions
Peyronie's Disease
Interventions
AA4500
Biological
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years and older · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
Burbank, California
Conditions
Cellulite
Interventions
Collagenase Clostridium Histolyticum-Aaes, Lysteda 650 MG Oral Tablet
Drug
Lead sponsor
Luxurgery
Industry
Eligibility
18 Years to 55 Years · Female only
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
New York, New York
Not yet recruiting Early Phase 1 Interventional

Collagenase Injection for Spasticity Management

NCT07693569
Conditions
Spasticity
Interventions
XIAFLEX Collagenase injection
Biological
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 75 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Houston, Texas
Conditions
Cellulite
Interventions
Qwo
Drug
Lead sponsor
DMR Research, PLLC
Other
Eligibility
18 Years to 60 Years · Female only
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Westport, Connecticut
Conditions
Peyronie's Disease
Interventions
CCH administration, Control - Crossover to CCH, RestoreX
Drug · Device
Lead sponsor
Charitable Union for the Research and Education of Peyronie's Disease
Other
Eligibility
18 Years and older · Male only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Orem, Utah
Completed Phase 4 Interventional Results available

Retreatment of Recurrent Dupuytren's Contractures

NCT01498640
Conditions
Dupuytren's Disease
Interventions
Collagenase clostridium histolyticum
Biological
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
7
States / cities
Phoenix, Arizona • Rockford, Illinois • Indianapolis, Indiana + 4 more
Recruiting Not applicable Interventional Accepts healthy volunteers

Radiation Therapy for Dupuytren's Contracture Following Non-Surgical Release

NCT06330545
Conditions
Dupuytren Contracture
Interventions
Radiation therapy
Radiation
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
45 Years and older
Enrollment
95 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2032
U.S. locations
1
States / cities
Lebanon, New Hampshire
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Histopathology Following CCH Injection

NCT04236635
Conditions
Characteristics of Subcutaneous Tissue
Interventions
Collagenase Clostridium Histolyticum Single Injection Technique, Collagenase Clostridium Histolyticum Multiple Injection Technique
Drug
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years to 55 Years · Female only
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
2
States / cities
Montclair, New Jersey • New York, New York